Update on castrate-resistant prostate cancer: 2010 - PubMed (original) (raw)
Update on castrate-resistant prostate cancer: 2010
Kiran Lassi et al. Curr Opin Oncol. 2010 May.
Abstract
Purpose of review: Prostate cancer remains a medical dilemma and a major cause of morbidity and mortality in many western countries. It represents the most common cancer in US men, with an estimated 192 280 new cases diagnosed in 2009. The median survival for men with metastatic castrate-resistant prostate cancer is 1-2 years, with improvements in survival seen primarily with docetaxel-based therapies. The purpose of this article is to discuss developments of novel agents in the field of metastatic castration-resistant prostate cancer (CRPC), including new cytotoxic agents, immune-based therapies, circulating tumor markers and targeting agents.
Recent findings: During this past year, several promising approaches yielded disappointing results in the phase III setting (GVAX); nonetheless, expectations for other agents (Abiraterone, MDV3100, Zibotentan, immunotherapy agents) still remain high.
Summary: Systemic therapy options are limited in CRPC and survival benefit remains to be seen with the new therapies. Circulating tumor cells continue to provide important prognostic information and will likely become an important aspect of future clinical decision-making.
Similar articles
- Emerging therapies in castrate-resistant prostate cancer.
Lassi K, Dawson NA. Lassi K, et al. Curr Opin Oncol. 2009 May;21(3):260-5. doi: 10.1097/CCO.0b013e32832a1868. Curr Opin Oncol. 2009. PMID: 19363343 Review. - New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. Beltran H, et al. Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4. Eur Urol. 2011. PMID: 21592649 Review. - Recent advances in second-line treatment of castration-resistant prostate cancer.
Ong M, Winquist E. Ong M, et al. Curr Opin Support Palliat Care. 2011 Sep;5(3):199-205. doi: 10.1097/SPC.0b013e32834903aa. Curr Opin Support Palliat Care. 2011. PMID: 21734586 Review. - New developments in castrate-resistant prostate cancer.
Shore N, Mason M, de Reijke TM. Shore N, et al. BJU Int. 2012 Jun;109 Suppl 6:22-32. doi: 10.1111/j.1464-410X.2012.11217.x. BJU Int. 2012. PMID: 22672122 Review. - Therapies in development for castrate-resistant prostate cancer.
Harzstark AL, Ryan CJ. Harzstark AL, et al. Expert Rev Anticancer Ther. 2008 Feb;8(2):259-68. doi: 10.1586/14737140.8.2.259. Expert Rev Anticancer Ther. 2008. PMID: 18279066 Review.
Cited by
- A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer.
Kim S, Kim BJ, Kim I, Kim JH, Kim HK, Ryu H, Choi DR, Hwang IG, Song H, Kwon JH, Jung JY, Han B, Zang DY. Kim S, et al. J Cancer. 2022 Feb 14;13(4):1363-1369. doi: 10.7150/jca.70385. eCollection 2022. J Cancer. 2022. PMID: 35281880 Free PMC article. - Integrative proteomic and phosphoproteomic profiling of prostate cell lines.
Katsogiannou M, Boyer JB, Valdeolivas A, Remy E, Calzone L, Audebert S, Rocchi P, Camoin L, Baudot A. Katsogiannou M, et al. PLoS One. 2019 Nov 1;14(11):e0224148. doi: 10.1371/journal.pone.0224148. eCollection 2019. PLoS One. 2019. PMID: 31675377 Free PMC article. - Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.
Johnson BM, Radwan FFY, Hossain A, Doonan BP, Hathaway-Schrader JD, God JM, Voelkel-Johnson CV, Banik NL, Reddy SV, Haque A. Johnson BM, et al. J Cell Biochem. 2019 Apr;120(4):6264-6276. doi: 10.1002/jcb.27913. Epub 2018 Oct 30. J Cell Biochem. 2019. PMID: 30378157 Free PMC article. - Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
Matsubara N, Mukai H, Hosono A, Onomura M, Sasaki M, Yajima Y, Hashizume K, Yasuda M, Uemura M, Zurth C. Matsubara N, et al. Cancer Chemother Pharmacol. 2017 Dec;80(6):1073-1077. doi: 10.1007/s00280-017-3433-3. Cancer Chemother Pharmacol. 2017. PMID: 29063294 Free PMC article. No abstract available. - Revisiting GM-CSF as an adjuvant for therapeutic vaccines.
Zhao W, Zhao G, Wang B. Zhao W, et al. Cell Mol Immunol. 2018 Feb;15(2):187-189. doi: 10.1038/cmi.2017.105. Epub 2017 Oct 23. Cell Mol Immunol. 2018. PMID: 29057973 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous